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Background: This study aims to evaluate the efficacy of the photobiomodulation therapy (PBMT) - in terms of 
pain and of quality of life- in patients affected by burning mouth syndrome (BMS).
Material and Methods: This study was designed as a randomised double-blinded prospective study. Patients diag-
nosed with BMS in the period from June 2015 to June 2018 were recruited. The patients were randomised into two 
groups and each received treatment once a week for ten weeks: group A received laser therapy (K Laser Cube 3®) 
while group B was given sham therapy (placebo). Pain was evaluated through the Visual Analogue Scale (VAS) 
and quality of life was assessed with the short form of the Oral Health Impact Profile (OHIP-14). Assessment was 
done at baseline and after every therapy session. The researchers were blind to the randomised allocations.
Results: A total of 85 patients were analysed. Group A (laser treatment) was composed of 43 patients while 
group B (sham therapy) of 42 patients. Patients treated with PBMT showed a significant decrease in symptoms 
(p=0.0008) and improved quality of life related to oral health (p=0.0002). Conclusions:  PBMT has demonstrated 
to have a positive effect in relieving BMS symptoms and in improving a patient’s overall quality of life. 
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Introduction
Burning Mouth Syndrome (BMS) is a complex disorder 
characterised by a burning or stinging sensation in the 
oral mucosa without any detectable changes upon phys-
ical examination. This disorder is sometimes accompa-
nied by dysgeusia and xerostomia (1). The continuous 
sensation of burning or heat usually affects the tongue 
(particularly the tip and lateral borders), but it can also 
affect the lips or the hard/soft palate (2-3). BMS most 
commonly occurs in patients over the age of 50, with a 
male-female ratio of 1:7; its reported prevalence from 
several international studies varies from 0.7 to 4.6% (4). 
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two groups: group A, patients who underwent laser 
therapy, and group B, patients who received sham ther-
apy (placebo) i.e. the device was turned on but the hand 
piece did not work. Laser/sham therapy was dispensed 
once a week for ten weeks. The researchers were blind 
to the randomised allocations.
The laser instrument used for this trial was K Laser 
Cube 3®; it was portable and easy to handle. The la-
ser was applied by a trained dentist and irradiated the 
most painful areas in the oral cavity, with discontinuous 
combined wavelengths between 660-970 nm, medium 
power 3.2 W (6.4 W pulsed at 50%), treatment time 
3’51”, frequency 1-20000Hz, spot size 1cm2.
Dentists and patients wore appropriate protective eye-
wear and international safety procedures were followed.
- Pain Scoring
Burning mouth symptoms were evaluated through the 
Visual Analogue Scale (VAS). In this system, zero in-
dicates no pain and ten indicates severe pain; patients 
were asked to select a number from 0 to 10 on a ruler 
with faces depicting the intensity of their pain. Pain as-
sessment was performed at baseline, after each laser 
treatment, and at a month follow-up.  Clinicians who 
performed the laser-treatments did not participate in the 
pain scoring.
- Quality of life related to Oral Health
The Italian version of the Oral Health Impact Profile 
questionnaire (OHIP-14) was also provided to evalu-
ate the quality of life related to oral health (QLROH), 
during the first visit and once again after the last laser 
session. The short form of the OHIP-14 questionnaire, 
consisting of 14 questions related to oral health, was 
used to evaluate the quality of life (QoL) in relation to 
oral health. The Italian version of the OHIP-14 has al-
ready been validated (23) and summarises the following 
seven domains of impact on daily activities as a result of 
oral problems: functional limitation (domain 1), physi-
cal pain (domain 2), psychological discomfort (domain 
3), physical activity (domain 4), psychological disability 
(domain 5), social disability (domain 6) and handicap or 
disability (domain 7).
The questionnaires were administered in interview 
form at baseline and at the end of each treatment ses-
sion. Clinicians who performed the laser-treatments did 
not participate in the quality of life assessment.
- Statistical analysis
Data was recorded on spread-sheets and a statistical 
analysis was conducted using Stata® software for Mac; 
sex, age, localization were examined through descrip-
tive analysis, including mean, standard deviation and 
percentiles.
Concordance or differences in the frequency distribu-
tion between the 2 groups were tested using Student 
t test; the variables were evaluated through split-plot 
analysis of variance (ANOVA) for repeated measure-
The aetiology of BMS can be attributed to numerous 
local and systemic factors (5); such local factors include 
parafunctional habits, badly fitting prostheses, allergic 
reactions, infections, taste alterations and xerostomia. 
Associated systemic factors are: endocrine alterations 
(hypothyroidism, diabetes, and the menopause), vita-
min B complex, iron and zinc deficiencies, anaemia, 
gastro esophageal reflux and Sjogren’s syndrome have 
been studied (5). For several years, BMS was also at-
tributed to psychological factors, such as anxiety, de-
pression and psychological stress (6). In addition, recent 
studies (7-9) have explored the possible pathophysiolog-
ical contribution of neuropathic mechanisms acting on 
different levels of the neuraxis (2).
Being a multifactorial disease, the treatment or elimina-
tion of a systemic, local or psychological factor often 
determines improvement of BMS pain and symptoms. 
If causal therapy does not work, symptom management 
varies from topical treatment- i.e. epithelial protector, 
capsaicin, aloe vera, topical clonazepam and lidocaine 
(10-12) - to systemic drugs, including systemic cap-
saicin, clonazepam, alpha lipoid acid (ALA), vitamin 
supplement, zinc replacement and selective serotonin 
inhibitors; in addition, psychotherapy and behavioural 
therapy can also help to reduce or eliminate pain or 
burning (2,12,13).
In recent years, the use of biostimulating lasers has 
been proposed in several medical fields for treating 
chronic and acute pain conditions (14,15); promoting 
re-epithelialization, fibroblasts proliferation, collagen 
synthesis, increasing vascularity and decreasing the 
alterations in nerve impulse conduction. It is therefore 
clear to say that laser has demonstrated to have an anti-
inflammatory and analgesic effect  (16-22).
This paper aims to assess whether photobiomodula-
tion therapy (PBMT) leads to an improvement in terms 
of both pain and quality of life in patients affected by 
Burning Mouth Syndrome.
Material and Methods
Patients eligible for this study were recruited at the De-
partment of Oral Medicine of Spedali Civili of Bres-
cia (Italy) in the period from June 2015 to June 2018. 
Patients who had complained of oral pain or burning 
for more than 6 months were examined under standard-
ized conditions, with artificial light, disposable retrac-
tors, and a mirror. Exclusion criteria were: age under 18 
years, pregnancy, oral mucosal lesions, systemic diseas-
es (hypertension, diabetes, anaemia, vitamin B12 or fo-
lic acid deficiency.), gastro-esophageal reflux, Sjogren’s 
syndrome, allergies, and hyposalivation. After the first 
visit, each patient underwent an oral swab. In case of 
positivity to Candidida or other microorganisms, the 
patient was excluded from the study.
Patients were then randomized by a computer code into 
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ments as to identify possible associations between oral 
health and QoL. The results of VAS were compared us-
ing Wilcoxon test. A p-value <0.05 was considered sta-
tistically significant. 
We hypothesised for there to be a 90% success rate at 
the end of the treatment for the group treated by laser 
and 60% for the placebo group. The minimum number 
of patients needed for the study, assuming alpha to be 
0.05 and beta 0.10 (study power=90%), was calculated 
to be 78 (at least 39 participants per group).
- Ethical consideration
The study was approved by the local Ethical Committee 
(NP 1811-14) and all the patients were informed about 
the research and signed an informed consent before par-
ticipating in the study.
Results
A total of 90 patients were included in the study according 
to the enrolment criteria (45 patients per group); out of the 
sample that started the study, 85 completed it (Fig.1).
The scores for OHIP-14 index are displayed in table 2. The 
bivariate analysis showed that the use of PBMT was sta-
tistically associated with an improvement in the quality of 
life related to oral health after the 7th week of treatment till 
the follow-up (Table 2).
Fig. 1: Enrollment.
Group A (laser treatment) was composed of 43 people, 
while group B (sham therapy) of 42 people. Demographic 
distribution and clinical data of the subjects are displayed 
in Table 1.
At baseline (T0), the VAS score was similar in the two 
groups (p=0.75). After the 5th therapy session (halfway 
through the full course of treatment), there was a reduction 
of the VAS mean; however, there still was not a statisti-
cally significant difference between group A and group B 
(p=0.6232). After the complete course of therapy, the pa-
tients treated with PBMT showed a significant decrease in 
symptoms (p=0.0008), which was maintained at the one-
month follow-up (p=0.0005).













Buccal mucosa 18 20
Other 5 3
Table 1: Demographic characteristics of the patients who completed 
the trial.
T0 (Baseline) T1 T2 T3 T4 T5
Group A 16.09±4.2 15.43±3.76 14.86±4.05 12.87±6.52 11.87±7.22 10.39±4.94
Group B 15.26±3.75 14.1±2.98 13.98±5.37 13.08±4.92 12.55±5.1 11.51±7.07
p-value 0.3701 0.0944 0.4248 0.8756 0.6398 0.4280
T6 T7 T8 T9 T10 1 month 
follow-up
Group A 9.87±7.21 8.78±3.22 8.12±1.59 7.88±4.08 7.09±2.59 7.34±3.78
Group B 11.99±2.48 11.01±5.65 11.58±3.13 11.03±5.10 10.64±4.13 10.43±2.99
p-value 0.0946 0.0385* 0.0000* 0.0042* 0.0000* 0.0002*
*significant for p<0.05
Analysis of Variance (ANOVA test) followed by HSD Post-Hoc test.
Table 1: OHIP-14 scores (mean±SD) in group A and group B at baseline (T0), after every treatment and at one-month 
follow-up.
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Discussion
This randomized double-blinded prospective study 
demonstrates the efficacy of laser therapy in the treat-
ment of Burning Mouth Syndrome.
In regards to the sample’s demographic characteristics, 
it is interesting to note that all the patients enrolled were 
female and middle-aged, upholding data reported in lit-
erature.
At the beginning of the trial, all patients complained 
of BMS symptoms, which reduced during the study 
period; both for VAS and for OHIP-14 index, cutback 
was significant only in the second half of the trial; this 
confirms that VAS improvement has a positive impact 
on quality of life.
Even if the exact mechanisms through which the la-
ser works for pain relief are still not clear, it has been 
demonstrated that laser light has three main effects: 
analgesia, anti-inflammation and promoting wound 
healing (24,25). During its interactions with biological 
tissues, laser energy is converted into energy useful to 
cells (18); it induces an augmented production of mito-
chondrial ATP production, serotonin and endorphins. 
Moreover, local blood circulation, cellular prolifera-
tion and protein synthesis are increased. It is known 
that anti-inflammation and analgesia are connected to 
both an increase of peripheral endogenous opioids and 
a decrease of pro-inflammatory cytokines and free oxy-
gen radicals (16). A recent trial of Pezelj-Ribaric, et al. 
(20) demonstrated that salivary levels of TNF-alpha and 
IL-6 in patients affected by BMS significantly reduced 
after 4 weeks of treatment with low level laser therapy 
(LLLT), with clinical improvement of BMS symptoms. 
Since the salivary levels of pro-inflammatory cytokines 
can be used as biological indicators of BMS (26), we can 
speculate that laser therapy with its mechanism of ac-
tion can be useful in disease management, as suggested 
in the present trial.
This double-blind study was conducted with a treatment 
and a placebo arm; a recent review of Kuten-Shorrer, 
et al. (27) found that, even if a lot of randomized con-
trolled studies were conducted about BMS treatment, 
the selection of a placebo was inconsistent. It is known 
that BMS is not always only a physical disease but also 
a psychological problem; this leads to evaluate that the 
placebo effect must be strongly considered when inves-
tigating the improvement of symptoms. The cited re-
view reported a mean placebo response as a fraction of 
treatment response of about 72%, which can be consid-
ered a very strong placebo response. In literature, about 
60% of studies about BMS therapy showed improve-
ment in the treated sample but a positive response to 
the placebo ranging from 15% to 74% (28,29) was also 
exhibited. Given the subjective nature of BMS symp-
toms and the strong placebo response, Kuten-Shorren, 
et al. (27) suggested to include a third arm in the BMS 
treatment randomized control trials (RCTs) made up of 
a no-treatment waitlist control group; the absence of 
this type of arm could be considered a weak point of the 
present survey.
The positive results of our investigation support the 
choice of PBMT for treating BMS symptoms. Previous 
studies have been conducted, studying the influence of 
varying laser device parameters such as power, wave-
lengths and number of sessions, but in general PBMT 
resulted in a significant improvement of the disease 
(14,21,30,31). More RCTs studies are needed to define 
specific device parameters and protocols to be applied 
in the everyday clinical management of BMS.
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